title: Effect of glibenclamide on antinociceptive effects of antidepressants of different classes.
abstract: OBJECTIVE
  The purpose of this work was to determine whether the intraperitoneal administration of glibenclamide as a K ATP channel blocker could have an effect on the antinociceptive effects of antidepressants with different mechanisms of action.
  
  
  METHODS
  Three antidepressant drugs, amitriptyline as a dual-action, nonselective inhibitor of noradrenaline and a serotonin reuptake inhibitor, fluvoxamine as a selective serotonin reuptake inhibitor and maprotiline as a selective noradrenaline reuptake inhibitor, were selected, and the effect of glibenclamide on their antinociceptive activities was assessed in male Swiss mice (25-30 g) using a formalin test.
  
  
  CONCLUSIONS
  None of the drugs affected acute nociceptive responses during the first phase. Amitriptyline (5, 10 mg/ kg), maprotiline (10, 20 mg/kg) and fluvoxamine (20 and 30 mg/kg) effectively inhibited pain induction caused by the second phase of the formalin test. Glibenclamide (5 mg/kg) alone did not alter licking behaviors based on a comparison with the control group. However, the pretreatment of animals with glibenclamide (10 and 15 mg/kg) partially reversed the antinociceptive effects of fluvoxamine but not those of maprotiline. In addition, the highest dose of glibenclamide (15 mg/kg) partially prevented the analgesic effect of amitriptyline.
  
  
  CONCLUSIONS
  Therefore, it seems that adenosine triphosphate-dependent potassium channels have a major role in the analgesic activity of amitriptyline and fluvoxamine.
authors.affiliation: Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. vhajhashemi@gmail.com
authors.forename: Valiollah
authors.initials: V
authors.lastname: Hajhashemi
authors.forename: Bahareh
authors.initials: B
authors.lastname: Amin
mesh_terms: D000639:Amitriptyline / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D004347:Drug Interactions; D016666:Fluvoxamine / Q000627:therapeutic use; D005905:Glyburide / Q000494:pharmacology*; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use; D051379:Mice; D023421:Models, Animal; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy; D010147:Pain Measurement / Q000187:drug effects*; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects*; D011897:Random Allocation
chemical_list: D000700:Analgesics; D000928:Antidepressive Agents; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D000639:Amitriptyline; D008376:Maprotiline; D016666:Fluvoxamine; D005905:Glyburide